Skip to main content

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights

Breast Cancer, Oncology
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
Read More
Lung Cancer, Oncology
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases
Wayne Kuznar
Read More
Breast Cancer, Oncology
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer
Wayne Kuznar
Read More
Lung Cancer, Oncology
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
Read More
Practice Management
Overcoming Barriers to Cost Transparency in Cancer Care
Chase Doyle
Read More
Practice Management
Novel Cancer Drugs Must Adopt Value-Based Pricing
Chase Doyle
Read More
Leukemia, Oncology
ASCO 2017: Acute Myeloid Leukemia Highlights
Read More
Practice Management
Proactive Symptom Self-Reporting Extends Survival in Patients with Metastatic Cancer
Phoebe Starr
Read More
Practice Management
Patients with Curable Cancer Experience Significant Symptom Burden and Hospitalization
Chase Doyle
Read More
Multiple Myeloma, Oncology
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
Read More
Page 1 of 3
Results 1 - 10 of 27